🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Dakota Gold And 2 Other Stocks Under $3 Insiders Are Buying

Published 15/02/2024, 11:57
© Reuters.  Dakota Gold And 2 Other Stocks Under $3 Insiders Are Buying
LUMN
-
ORGS
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed higher by more than 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Lumen Technologies

  • The Trade: Lumen Technologies, Inc. (NYSE: LUMN) Director James Fowler acquired a total of 33,500 shares an average price of $1.68. To acquire these shares, it cost around $56,428.
  • What’s Happening: Lumen Technologies reported better-than-expected fourth-quarter financial results.
  • What Lumen Technologies Does: With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises.
Dakota Gold
  • The Trade: Dakota Gold Corp. (NYSE: DC) Director Robert Quartermain acquired a total of 10,000 shares at at an average price of $2.00. To acquire these shares, it cost around $20,000.
  • What’s Happening: The company’s stock lost around 33% over the past six months.
  • What Dakota Gold Does: Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota.
Check This Out: Investor Sentiment Improves; Dow Jumps Over 150 Points

Orgenesis

  • The Trade: Orgenesis Inc. (NASDAQ: ORGS) 10% owner Jacob Safier acquired a total of 365,140 shares at an average price of $0.58. The insider spent around $213,280 to buy those shares.
  • What’s Happening: Orgenesis entered into a definitive agreement with MM OS Holdings, an affiliate of Metalmark Capital Partners, to acquire its approximate 25% stake in Octomera.
  • What Orgenesis Does: Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies.
Don’t forget to check out our premarket coverage here

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.